{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.8","upperLimit":"99.7","value":"88.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"ORR by Independent Review Committee. ORR is the percent of participants with best overall response of complete response (CR) or partial response (PR).\n\nComplete response via PET-CT:\n\n* Lymph nodes/extralymphatic: Score 1, 2, 3a with/without residual mass on 5-point scale\n* New lesions: No\n* Bone marrow: No FDG-avid disease\n\nComplete response via CT scan:\n\n* Lymph nodes/extralymphatic: Target nodes/nodal masses ≤ 1.5 cm longest transverse diameter.\n* Nonmeasured lesion: None\n* New lesions: No\n* Bone marrow: Normal\n\nPartial response via PET-CT:\n\n* Lymph nodes/extralymphatic: Score 4, 5b, reduced uptake from baseline\n* New lesions: None\n* Bone marrow: Residual uptake higher than normal, reduced from baseline\n\nPartial response via CT scan:\n\n* Lymph nodes/extralymphatic: 50% decrease in sum of diameters of \\<= 6 target measurable nodes/extranodal sites\n* Nonmeasured lesion: None/normal\n* Organ enlargement: Spleen length decreased \\> 50%\n* New lesions: No","dispersionType":"95% Confidence Interval","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"NUMBER","populationDescription":"All participants in the JCAR017 treated set. Prespecified to be reported for cohort 7 only.","reportingStatus":"POSTED","timeFrame":"From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)","title":"Overall Response Rate (ORR) in Cohort 7","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}